3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition

被引:66
作者
Patil, Vishal [1 ]
Sodji, Quaovi H. [1 ]
Kornacki, James R. [3 ,4 ]
Mrksich, Milan [3 ,4 ]
Oyelere, Adegboyega K. [1 ,2 ]
机构
[1] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA
[2] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA
[3] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[4] Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA
关键词
MATRIX-METALLOPROTEINASE INHIBITORS; METAL-COMPLEXES; CANCER-THERAPY; DESIGN; ACETYLATION; SOLUBILITY; CHEMISTRY; ACID;
D O I
10.1021/jm301769u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated research efforts aimed at finding alternative nonhydroxamate ZBGs. We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively. Remarkably, 3-HPT gives no inhibition of HDAC 1. Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8. Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.
引用
收藏
页码:3492 / 3506
页数:15
相关论文
共 47 条
[21]   In Vitro Solubility Assays in Drug Discovery [J].
Kerns, Edward H. ;
Di, Li ;
Carter, Guy T. .
CURRENT DRUG METABOLISM, 2008, 9 (09) :879-885
[22]   Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors [J].
Khan, Nagma ;
Jeffers, Michael ;
Kumar, Sampath ;
Hackett, Craig ;
Boldog, Ferenc ;
Khramtsov, Nicholai ;
Qian, Xiaozhong ;
Mills, Evan ;
Berghs, Stanny C. ;
Carey, Nessa ;
Finn, Paul W. ;
Collins, Laura S. ;
Tumber, Anthony ;
Ritchie, James W. ;
Jensen, Peter Buhl ;
Lichenstein, Henri S. ;
Sehested, Maxwell .
BIOCHEMICAL JOURNAL, 2008, 409 :581-589
[23]   Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome [J].
Kornberg, RD ;
Lorch, YL .
CELL, 1999, 98 (03) :285-294
[24]   RETRACTED: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Retracted Article) [J].
Kulp, Samuel K. ;
Chen, Chang-Shi ;
Wang, Da-Sheng ;
Chen, Ching-Yu ;
Chen, Ching-Shih .
CLINICAL CANCER RESEARCH, 2006, 12 (17) :5199-5206
[25]   Synthesis, structure and spectroscopy of new thiopyrone and hydroxypyridinethione transition-metal complexes [J].
Lewis, JA ;
Tran, BL ;
Puerta, DT ;
Rumberger, EM ;
Hendrickson, DN ;
Cohen, SM .
DALTON TRANSACTIONS, 2005, (15) :2588-2596
[26]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[27]   Histone deacetylase inhibitors [J].
Miller, TA ;
Witter, DJ ;
Belvedere, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (24) :5097-5116
[28]   NEW STEREOSPECIFIC CROSS-COUPLING BY THE PALLADIUM-CATALYZED REACTION OF 1-ALKENYLBORANES WITH 1-ALKENYL OR 1-ALKYNYL HALIDES [J].
MIYAURA, N ;
YAMADA, K ;
SUZUKI, A .
TETRAHEDRON LETTERS, 1979, 20 (36) :3437-3440
[29]   Histone deacetylase inhibitors [J].
Monneret, C .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (01) :1-13
[30]  
Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO